You are here:
EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a preventive vaccine against diseases caused by the Epstein-Barr virus (EBV). The aim is to protect people from a range of serious…
In 2021, a research team led by Prof. Heiko Lickert from Helmholtz Munich discovered the insulin-inhibitory receptor "Inceptor" and its role as a suppressor of the insulin signaling pathway. Now, the researchers have unlocked another, even more…
The Life Science Factory has opened its new site on the Helmholtz campus in Munich. Beginning in 2025, around 1,800 square meters of state-of-the-art laboratories and a flexible co-working space will be available for life science start-ups and…
On June 12, 2024, the National Strategy for Gene and Cell Therapies was unveiled at the Futurium in Berlin.
In an ongoing phase 1 clinical trial targeting malignant glioblastoma, the initial patient has received a dosage of a novel drug candidate, derived from an antibody originating at Helmholtz Munich. This innovative compound, coupled with a…
In a new collaboration, the Computational Health Center at Helmholtz Munich has teamed up with the global pharmaceutical company Pfizer. The joint initiative, spanning three years, aims to leverage Pfizer's vast knowledge and accumulated data in…
We use cookies to improve your experience on our Website. We need cookies to continually improve our services, enable certain features, and when we embed third-party services or content, such as the Vimeo video player. In such cases, information may also be transferred to third parties. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here:
